'Not colonial' Sanofi initiates KiDS in India
This article was originally published in Scrip
Sanofi is not a colonial company, said CEO Christopher Viehbacher at a media briefing in Mumbai on 30 September 2013. Addressing both the technology transfer agenda and Indian sensitivities to multinationals that appear to act in an imperialist fashion, it is not a firm that simply discovers and produces medicines in its home country and essentially looks for export markets, said Mr Viehbacher.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.